These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 32557659)

  • 21. Construction of CAR-T cells targeting TM4SF1 and its anti-tumor capacity in ovarian cancer.
    Shen Y; Liu G; Zhang Q; Tian X; Ouyang L; Zhang L
    Immunol Lett; 2023 Mar; 255():1-9. PubMed ID: 36739093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The challenge of selecting tumor antigens for chimeric antigen receptor T-cell therapy in ovarian cancer.
    Ding H; Zhang J; Zhang F; Xu Y; Yu Y; Liang W; Li Q
    Med Oncol; 2022 Sep; 39(12):232. PubMed ID: 36175774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape.
    Hamieh M; Dobrin A; Cabriolu A; van der Stegen SJC; Giavridis T; Mansilla-Soto J; Eyquem J; Zhao Z; Whitlock BM; Miele MM; Li Z; Cunanan KM; Huse M; Hendrickson RC; Wang X; Rivière I; Sadelain M
    Nature; 2019 Apr; 568(7750):112-116. PubMed ID: 30918399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T-Cell Receptor Therapy in the Treatment of Ovarian Cancer: A Mini Review.
    Wu JWY; Dand S; Doig L; Papenfuss AT; Scott CL; Ho G; Ooi JD
    Front Immunol; 2021; 12():672502. PubMed ID: 33927729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospects of chimeric antigen receptor T cell therapy in ovarian cancer.
    Jindal V; Arora E; Gupta S; Lal A; Masab M; Potdar R
    Med Oncol; 2018 Apr; 35(5):70. PubMed ID: 29651744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer.
    Chodon T; Lugade AA; Battaglia S; Odunsi K
    Hematol Oncol Clin North Am; 2018 Dec; 32(6):1025-1039. PubMed ID: 30390758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
    Ti D; Niu Y; Wu Z; Fu X; Han W
    Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy.
    Rodriguez-Garcia A; Lynn RC; Poussin M; Eiva MA; Shaw LC; O'Connor RS; Minutolo NG; Casado-Medrano V; Lopez G; Matsuyama T; Powell DJ
    Nat Commun; 2021 Feb; 12(1):877. PubMed ID: 33563975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
    Martinez M; Moon EK
    Front Immunol; 2019; 10():128. PubMed ID: 30804938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multi-Specific CAR Targeting to Prevent Antigen Escape.
    Walsh Z; Ross S; Fry TJ
    Curr Hematol Malig Rep; 2019 Oct; 14(5):451-459. PubMed ID: 31332617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells.
    Hughes-Parry HE; Cross RS; Jenkins MR
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31892219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer.
    Klapdor R; Wang S; Morgan M; Dörk T; Hacker U; Hillemanns P; Büning H; Schambach A
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
    Siegler EL; Wang P
    Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Basics of immunotherapy for epithelial ovarian cancer.
    Bund V; Azaïs H; Bibi-Triki S; Lecointre L; Betrian SB; Angeles MA; Eberst L; Faller E; Boisramé T; Bendifallah S; Akladios C; Deluche É;
    J Gynecol Obstet Hum Reprod; 2022 Feb; 51(2):102283. PubMed ID: 34875397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
    Mohammed S; Sukumaran S; Bajgain P; Watanabe N; Heslop HE; Rooney CM; Brenner MK; Fisher WE; Leen AM; Vera JF
    Mol Ther; 2017 Jan; 25(1):249-258. PubMed ID: 28129119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.
    Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K
    Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CAR T Cell Therapy for Solid Tumors.
    Newick K; O'Brien S; Moon E; Albelda SM
    Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.
    Koneru M; O'Cearbhaill R; Pendharkar S; Spriggs DR; Brentjens RJ
    J Transl Med; 2015 Mar; 13():102. PubMed ID: 25890361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.